A medication that has been studied as an anticancer agent shows promise for the treatment of Alzheimer’s disease, according to researchers.
Scientists studying bryostatin in laboratory mice have observed that the drug effectively stops the Alzheimer’s disease process. The drug reduces brain levels of amyloid-beta protein, which are elevated in Alzheimer’s patients.
Bryostatin also was shown to enhance learning and memory retention of rats in a maze task, according to the published report of the study in the Proceedings of the National Academy of Sciences.
(Published 10-31-05)
